Affiliation:
1. Institute for Atherosclerosis Research, Osennyaya 4-1-207, 121609 Moscow, Russia
2. Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, 125315 Moscow, Russia
3. Petrovsky National Research Centre of Surgery, 2, Abrikosovsky Lane, 119991 Moscow, Russia
Abstract
It is known that lipid metabolism disorders are involved in a wide range of pathologies. These pathologies include cardiovascular, metabolic, neurodegenerative diseases, and even cancer. All these diseases lead to serious health consequences, which makes it impossible to ignore them. Unfortunately, these diseases most often have a complex pathogenesis, which makes it difficult to study them and, in particular, diagnose and treat them. HDL is an important part of lipid metabolism, performing many functions under normal conditions. One of such functions is the maintaining of the reverse cholesterol transport. These functions are also implicated in pathology development. Thus, HDL contributes to vascular protection, which has been demonstrated in various conditions: Alzheimer’s disease, atherosclerosis, etc. Many studies have shown that serum levels of HDL cholesterol correlate negatively with CV risk. With these data, HDL-C is a promising therapeutic target. In this manuscript, we reviewed HDL-based therapeutic strategies that are currently being used or may be developed soon.
Funder
Russian Science Foundation
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference84 articles.
1. HDL and Reverse Cholesterol Transport;Ouimet;Circ. Res.,2019
2. ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: Important targets for the treatment of atherosclerosis;Ye;Curr. Drug Targets,2011
3. HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack;Hassan;Glob. Cardiol. Sci. Pr.,2014
4. HPS2-THRIVE Collaborative Group (2014). Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med., 371, 203–212.
5. AIM-HIGH Investigators, Boden, W.E., Probstfield, J.L., Anderson, T., Chaitman, B.R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., and Weintraub, W. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 365, 2255–2267.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献